Viatris to Acquire Pacira Biosciences for $36.50 Per Share in Cash

The all-cash structure matters more than the headline price: it hands Pacira holders a clean exit rather than exposure to the combined entity, and it signals Viatris is buying established revenue rather than pipeline optionality. The long runway to closing, stretching to end-2026, leaves room for regulatory review and for the deal's economics to be tested against Pacira's performance in the interim. Whether the cash consideration holds if conditions shift before then is the open question.